Get the Stockscreener App
2.92
3.18%
0.09
iBio Inc stock is traded at $2.92, with a volume of 281.28K.
It is up +3.18% in the last 24 hours and up +17.74% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$2.83
Open:
$2.88
24h Volume:
281.28K
Relative Volume:
2.47
Market Cap:
$27.42M
Revenue:
$2.05M
Net Income/Loss:
$-27.28M
P/E Ratio:
-0.1944
EPS:
-15.02
Net Cash Flow:
$-18.89M
1W Performance:
+6.96%
1M Performance:
+17.74%
6M Performance:
+35.81%
1Y Performance:
+175.97%
1-Day Range:
$2.73
$3.07
1-Week Range:
$2.66
$3.07
52-Week Range:
$1.03
$4.98
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
2.92 | 27.42M | 2.05M | -27.28M | -18.89M | -15.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
I: Weekly TechBio News - substack.com
iBio Inc. stock rises Wednesday, outperforms market - MarketWatch
iBio Announces Successful Closing of Private Placement OfferingOn January 10, 2025, iBio, Inc. (NYSE American: IBIO) announced the completion of a private placement offering, marking an important development for the company. The securities purchase a - Defense World
iBio director Parada acquires $499,998 in common stock By Investing.com - Investing.com Australia
iBio director William Clark purchases $4,999 in common stock By Investing.com - Investing.com Australia
Felipe Duran Increases Stake in iBio Inc with Recent Share Purch - GuruFocus.com
Director David Arkowitz Acquires 18,382 Shares of iBio Inc (IBIO) - GuruFocus.com
Insider Buying: Gary Sender Acquires 9,191 Shares of iBio Inc (I - GuruFocus.com
Ibio's chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Australia
iBio director Gary Sender purchases $24,999 in common stock By Investing.com - Investing.com Australia
Ibio CEO Brenner Martin acquires $24,999 in stock By Investing.com - Investing.com Australia
Ibio's CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Australia
iBio director Arkowitz purchases $49,999 in common stock By Investing.com - Investing.com Australia
Ibio’s CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Nigeria
Ibio’s chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Nigeria
iBio director William Clark purchases $4,999 in common stock - Investing.com India
iBio director Arkowitz purchases $49,999 in common stock - Investing.com India
iBio Inc. stock falls Monday, underperforms market - MarketWatch
Ibio's CFO Duran Felipe buys $24,999 in common stock - Investing.com
iBio Announces New Investments from Board Members and Officers - The Manila Times
iBio Board Backs AI-Driven Obesity Drug Platform with $650K Strategic Investment - StockTitan
** - Defense World
iBio Advances Antibody Development for Obesity Treatment - TipRanks
Ibio licenses long-acting anti-myostatin antibody from Astralbio - BioWorld Online
iBio develops antibody for cardiometabolic disorders and obesity - Investing.com
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio - The Manila Times
iBio and AstralBio Breakthrough: Novel Antibody Targets Obesity and Diabetes Through Activin E Inhibition - StockTitan
iBio Inc. stock rises Monday, still underperforms market - MarketWatch
iBio Enters Exclusive License Agreement with AstralBio for Development of Anti-Myostatin Antibody - Defense World
SABBY MANAGEMENT, LLC Acquires 19,250 Shares of iBio Inc - GuruFocus.com
iBio Inc. stock rises Friday, still underperforms market - MarketWatch
iBio Expands Pipeline with New Antibody Agreement - Yahoo Finance
iBio Inc. stock falls Thursday, underperforms market - MarketWatch
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform - AOL
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio - The Manila Times
iBio expands cardiometabolic and obesity program (NYSE:IBIO) - Seeking Alpha
iBio (NYSE:IBIO) Stock Price Up 2.5% – Should You Buy? - Defense World
iBio Inc. stock rises Thursday, outperforms market - MarketWatch
iBio Inc. stock falls Wednesday, still outperforms market - MarketWatch
LUCID CAPITAL MARKETS Initiates Coverage of iBio (IBIO) with Buy Recommendation - MSN
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):